Cortecs International's Macritonin Phase II/III trials continuing.LONDON--(BUSINESS WIRE)--April 28, 1997--Cortecs International ("Cortecs") (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :DLVRY/LSE:COR/ASX:CRI CRI constant-rate infusion. ) the U.K. based pharmaceutical company, today announced it is currently awaiting the results of its ongoing Phase II/III clinical trials for Macritonin(TM), its lead osteoporosis therapeutic. These trials are conducted independently and, therefore, the Company has no control over the timing of the receipt of the information on the trials from the independent statisticians. The Company has now been advised that it will receive the data related to the trials not later that May 2, 1997. The Company will release the data as soon as practical thereafter. Cortecs is a British based company quoted on the London Stock Exchange London Stock Exchange London marketplace for securities. It was formed in 1773 by a group of stockbrokers who had been doing business informally in local coffeehouses. , the Australian Stock Exchange Australian Stock Exchange (ASX) Australia's major securities market, formed when the six state stock exchanges (Adelaide, Brisbane, Hobart, Melbourne, Perth, and Sydney stock exchanges) were merged in 1987. and on Nasdaq. The Company specializes in the development of new oral pharmaceutical delivery systems, new oral mucosal immunostimulants and point-of-care rapid diagnostics which provide the opportunity to advance the management of serious diseases. Cortecs also markets a range of ethical and OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). medicines and diagnostic products in the U.K. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like of Cortecs International Limited, are forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. Actual results or events could differ materially from those described in the forward looking statements due to a variety of factors, including those set forth in the Company's filings with the U.S. Securities and Exchange Commission. Press releases and other Cortecs International information are available on the Cortecs International web site: http://www.cortecs.com. CONTACT: Cortecs International Press Office John Barrington-Carver, 011-44-181-568-7071 -or- Kehoe, White, Savage & Company, Inc. John P. Kehoe/Van Negris, 212/888-1616 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion